Remission in CML: is DNA useful?

Abstract

Imatinib is the current standard of care for patients with CML; however, the ability of imatinib to eradicate the CML clone is uncertain. Indeed, according to in vitro studies, leukemic stem cells are seemingly resistant to imatinib-induced apoptosis.1 Thus, imatinib treatment would not appear to be curative. Most patients in longterm remission after… (More)
DOI: 10.1182/blood-2010-05-286310

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics